Novo Nordisk ADR (NVO) concluded trading on Wednesday at a closing price of $120.93, with 4.11 million shares of worth about $497.38 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 30.12% during that period and on Wednesday the price saw a loss of about -0.43%. Currently the company’s common shares owned by public are about 3.38B shares, out of which, 3.38B shares are available for trading.
Stock saw a price change of 0.78% in past 5 days and over the past one month there was a price change of 14.64%. Year-to-date (YTD), NVO shares are showing a performance of 16.90% which increased to 70.77% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $67.66 but also hit the highest price of $124.76 during that period. The average intraday trading volume for Novo Nordisk ADR shares is 4.43 million. The stock is currently trading 4.62% above its 20-day simple moving average (SMA20), while that difference is up 11.97% for SMA50 and it goes to 28.47% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Novo Nordisk ADR (NYSE: NVO) currently have 3.38B outstanding shares and institutions hold larger chunk of about 9.14% of that.
The stock has a current market capitalization of $409.16B and its 3Y-monthly beta is at 0.41. PE ratio of stock for trailing 12 months is 44.77, while it has posted earnings per share of $2.70 in the same period. Its PEG reads 15.99 and has Quick Ratio of 0.64 while making debt-to-equity ratio of 0.25. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVO, volatility over the week remained 2.46% while standing at 1.85% over the month.
Analysts are in expectations that Novo Nordisk ADR (NVO) stock would likely to be making an EPS of $0.78 in the current quarter, while forecast for next quarter EPS is $0.79 and it is $3.91 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.77 which is $0.79 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.64 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 23.33% while it is estimated to increase by 20.10% in next year. EPS is likely to shrink at an annualized rate of 2.80% for next 5-years, compared to annual growth of 16.48% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on January 23, 2024 offering an Overweight rating for the stock and assigned a target price of $120 to it. On December 01, 2023, Cantor Fitzgerald Initiated their recommendations, while on October 02, 2023, Argus Initiated their ratings for the stock with a price target of $110. Stock get a Buy rating from HSBC Securities on July 14, 2023.
